Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grammidin with Anesthetic Spray vs Septolete Total in Acute Pharyngitis
NCT06843018Phase 2Recruiting
- Sponsor
- Valenta Pharm
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gramicidin C + cetylpyridinium chloride in acute pharyngitis, nasopharyngitis and chronic pharyngitis (3 arms), sponsored by Valenta Pharm. Primary endpoint: Combined primary efficacy endpoint: Visual Analog Scale + Tonsillopharyngitis Assessment Score. Started Nov 2024; status: recruiting.
02
Drugs
gramicidin C + cetylpyridinium chloride
03
Conditions
acute pharyngitisnasopharyngitischronic pharyngitis
Beyond the preview
Go deeper on NCT06843018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843018.